XML 39 R8.htm IDEA: XBRL DOCUMENT
v3.25.2

NATURE OF OPERATIONS | 12 Months Ended
--- | ---
Mar. 31, 2025
Accounting Policies [Abstract] |
Nature of Operations [Text Block] | NOTE 1 – NATURE OF OPERATIONS IGC Pharma is on a mission to transform Alzheimer’s treatment. We are building a robust pipeline of drug candidates, each targeting different aspects of the disease. Our product candidate pipeline and anticipated milestones include the following: -
Asset |  | Target Indication |  | Mechanism of Action |  | Development Stage |  | Key Milestones
IGC- AD1 |  | Agitation in Alzheimer’s dementia |  | CB1 receptor partial agonist; reduces neuroinflammation and restores neurotransmitter balance |  | Phase 2 clinical trial (CALMA study) |  | Interim Phase 2 data analysis suggests cognitive improvements in the active treatment group versus the placebo group,
TGR-63 |  | Early to moderate Alzheimer’s disease |  | Disrupts amyloid-beta (Aβ) plaque formation; crosses blood-brain barrier |  | Preclinical |  | Demonstrated favorable safety profile; advancing towards clinical trials
LMP |  | Alzheimer’s disease |  | Targets neuroinflammation, neurotransmitter imbalance, and inflammasome-3 |  | Preclinical |  | Bioequivalence to IGC-AD1 anticipated in 2025
IGC-M3 |  | Early-stage Alzheimer’s disease |  | Inhibits Aβ plaque aggregation |  | Preclinical |  | Toxicology studies planned for mid-2025
IGC-1C |  | Alzheimer’s disease and metabolic disorders |  | Targets tau protein phase separation; potential GLP-1 receptor agonist |  | Preclinical |  | Exhibits strong binding affinity to tau protein; potential for weight loss applications
IGC-1A |  | Metabolic disorders (e.g., type 2 diabetes, obesity) |  | Potential GLP-1 and GIP receptor agonist; CB1 receptor inverse agonist |  | Preclinical |  | Identified through AI modeling; toxicology and dosing studies underway
This pipeline reflects IGC Pharma’s strategic focus on addressing neurodegenerative diseases, particularly Alzheimer’s, through innovative mechanisms targeting key pathological features like amyloid plaques and tau protein aggregation. Additionally, their expansion into metabolic disorders showcases the versatility of their drug discovery platform, leveraging artificial intelligence to identify promising therapeutic candidates. As of March 31, 2025, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), HH Processors, LLC, IGCare LLC, Sunday Seltzer LLC, IGC Pharma IP, LLC, IGC Pharma, LLC, SAN Holdings, LLC, Hamsa Biopharma India Pvt. Ltd. And Colombia-based beneficially-owned subsidiary IGC Pharma SAS. The Company’s fiscal year is the 52- or 53-week period that ends on March 31. The Company’ principal office is in Maryland established in 2005. Additionally, the Company has offices in Washington state, Colombia, South America, and India. The Company’s filings are available on www.sec.gov. During fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences. As a result, management determined that the Company operates as a single reportable segment, focused on the vision to make the world free from Alzheimer’s. Historically, the Company reported two operating segments: Life Sciences and Infrastructure. While the Infrastructure segment generated revenues in fiscal 2024, it did not generate any revenues in fiscal 2025 and is no longer actively managed or evaluated as a discrete operating segment by the Company’s Chief Operating Decision Maker. For more information, please refer to “Note 18 – Segment Information”.

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details
Name: | us-gaap_NatureOfOperations
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration